BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

ReproCELL Announces Approval for Listing on the Osaka Stock Exchange JASDAQ Market Growth


5/29/2013 9:24:15 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

YOKOHAMA, Japan, May 28, 2013 /PRNewswire/ --

ReproCELL Inc. (CEO: Chikafumi Yokoyama, Ph.D.) announced today that ReproCELL will proceed with an initial public offering (IPO) and has received formal approval from the Osaka Stock Exchange (OSE) for listing on the JASDAQ Market Growth. The listing date is set for June 26th, 2013 (Wednesday). ReproCELL will trade under the OSE listing code 4987.

ReproCELL Inc. was established in 2003 with the goal of contributing to people's health and welfare through the development of stem cell technologies by stem cell pioneers, Prof. Norio Nakatsuji from the Institute for Integrated Cell-Material Sciences, Kyoto University, and Prof. Hiromitsu Nakauchi from The Institute of Medical Sciences, The University of Tokyo.

ReproCELL is a world-leading pioneer in commercializing reagents for ES/iPS cells and human pluripotent stem cells as an effective tool for drug discovery and development. The company has successfully launched human iPS cell-derived cardiomyocytes, followed by the launch of human iPS cell-derived neurons, Alzheimer's disease model cells and hepatocytes for drug discovery.

Induced pluripotent stem cells or iPS cells, are a type of pluripotent stem cell artificially derived from a non-pluripotent cell - typically an adult somatic cell. For the discovery of iPS cells, Professor Shinya Yamanaka was awarded the Nobel Prize for Physiology or Medicine in October 2012.

For further information please visit https://www.reprocell.com/en/

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

ReproCELL
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES